Zonisamide vs placebo
It is very uncertain whether zonisamide changes adverse events Number of adverse events compared with placebo (very low certainty).
- RD 0.6 [0.28, 0.92]1 study · 20 participantsVery low
It is very uncertain whether zonisamide changes adverse events Number of adverse events compared with placebo (very low certainty).
It is very uncertain whether the intervention changes adverse events Number of adverse events (very low certainty).
Summary of findings: dopamine agonists leads to higher number of dropouts due to adverse events compared with placebo (high certainty).
Summary of findings: levodopa probably leads to lower number of drop outs due to adverse events compared with other dopamine agonists (moderate certainty).
Summary of findings: dopamine agonists probably leads to higher number of drop outs due to adverse events compared with levodopa (moderate certainty).
Summary of findings: dopamine agonists showed no clear difference in number of patients experiencing adverse events compared with levodopa (moderate certainty).